GH1 and Septo-optic dysplasia: Adolescents with radiologically confirmed substantial congenital midline defects affecting the hypothalamic-pituitary region, such as pituitary stalk interruption syndrome (PSIS) or septo-optic dysplasia (SOD) should continue GH therapy if they present with an additional deficiency of ≥ 2 other pituitary hormones.